Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-17 are pending. Applicants have amended claims 1, 10, 12 and 16 in the amendment filed on August 20, 2026. The claims 1-4, 8-10 are rejected, claims 5-7 are objected and claims 11-17 are considered allowable in this Office Action.
I. Response to Remarks
Applicants’ amendment, filed on August 20, 2026, has overcome the rejection of claims 1-17 under 35 USC 112(b) as being indefinite for the term “including”; the rejection of claims 10 and 16 under 35 USC 112(b) as being indefinite for the term “comprises”; and the objection of claims 10 and 16 for containing the phrase “and pharmaceutically acceptable salts” and not having the term “and” in between the last two structures listed in the claims. The above rejections and objections have been withdrawn.
II. Information Disclosure Statement
The information disclosure statement (IDS) submitted on August 20, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.
III. Rejection(s)
Claim Rejections - 35 USC § 112 (a)
The following is a quotation of the first paragraph of 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-4, 8-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The limitation “at least one active pharmaceutical ingredient (API)” has not been clearly defined in the specification so that one of ordinary skill in the art would know what active pharmaceutical ingredients are included and/or excluded. Applicants’ specification has provided support and written description of the API being selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir but has not provided written description of the API being any active agent in the combination. The API should be limited to what Applicants have clear support and description for in the specification to overcome the rejection.
IV. Objections
Dependent Claim Objections
Dependent Claims 5-7 are also objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim.
V. Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626